Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Massachusetts: - Beverly Hospital — Beverly, Massachusetts
- Tufts Medical Center — Boston, Massachusetts
- Boston Medical Center — Boston, Massachusetts
- Dana-Farber Cancer Institute at Boston Medical Center - Brighton — Brighton, Massachusetts
- Lahey Clinic — Burlington, Massachusetts
Phase 3 Recruiting Industry
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …
Sponsor: Pfizer
NCT ID: NCT07222800
Sites in Massachusetts: - Brigham and Women's Hospital (BWH) — Boston, Massachusetts
- Dana-Farber Cancer Institute (DFCI) — Boston, Massachusetts
- Dana-Farber Brigham Cancer Center - Foxborough — Foxborough, Massachusetts
- Dana-Farber Brigham Cancer Center at Milford Regional Medical Center — Milford, Massachusetts
- Dana-Farber Cancer Institute -Chestnut Hill — Newton, Massachusetts
Phase 3 Recruiting Industry
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…
Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Sites in Massachusetts: - Clinical Study Site — Boston, Massachusetts
- Clinical Study Site — Danvers, Massachusetts
- Clinical Study Site — Newton, Massachusetts
Phase 3 Recruiting Network
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limit…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06205485
Sites in Massachusetts: - Beverly Hospital — Beverly, Massachusetts
- Lahey Clinic — Burlington, Massachusetts
- Addison Gilbert Hospital — Gloucester, Massachusetts
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Sites in Massachusetts: - Local Institution - 0471 — Boston, Massachusetts
Phase 3 Recruiting Industry
The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to b…
Sponsor: Rapamycin Holdings Inc.
NCT ID: NCT06950385
Sites in Massachusetts: - Dana Farber Cancer Institute — Boston, Massachusetts
Phase 3 Recruiting Academic/Other
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Sites in Massachusetts: - Dana Farber Cancer Center, Harvard University — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Massachusetts: - Massachusetts General Hospital, — Boston, Massachusetts
- Local Institution - 1004 — Boston, Massachusetts
- Local Institution - 2131 — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Massachusetts: - Dana Farber Cancer Institute — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Massachusetts: - Dana-Farber Cancer Institute — Boston, Massachusetts
Phase 2 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given al…
Sponsor: AbbVie
NCT ID: NCT07023289
Sites in Massachusetts: - Massachusetts General Hospital /ID# 273608 — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in Massachusetts: - Dana Farber Cancer Institute — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy. Part 1 in…
Sponsor: Pfizer
NCT ID: NCT04557449
Sites in Massachusetts: - Brigham & Women's Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Dana Farber Cancer Institute- Chestnut Hill — Newton, Massachusetts
Phase 1, Phase 2 Recruiting Industry
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Sponsor: Verastem, Inc.
NCT ID: NCT07020221
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal …
Sponsor: Blueprint Medicines Corporation
NCT ID: NCT07629960
Sites in Massachusetts: - Massachusetts General Hospital - Main Campus — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of…
Sponsor: Neonc Technologies, Inc.
NCT ID: NCT06047379
Sites in Massachusetts: - Tufts Medical Center — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Sponsor: ModeX Therapeutics, An OPKO Health Company
NCT ID: NCT06239194
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
This is the first-in-human study of 7MW4911 in US patients, to investigate its prelimary safety and efficacy in patients with gastrointestinal cancers.
Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
NCT ID: NCT07216560
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
Phase 2 Recruiting Industry
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…
Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in Massachusetts: - Dana Farber Cancer Institute — Boston, Massachusetts
Phase 2 Recruiting Academic/Other
This is a multi-site, prospective, non-randomized phase 2 study evaluating neoadjuvant botensilimab in combination with balstilimab for patients with microsatellite stable (MSS) / mismatch repair proficient (MMRp) early rectal cancer stage…
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT07735624
Sites in Massachusetts: - Brigham and Women's Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Beth Israel Deaconess Medical Center (BIDMC) — Boston, Massachusetts
Phase 2 Recruiting Academic/Other
The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more …
Sponsor: Brigham and Women's Hospital
NCT ID: NCT04899908
Sites in Massachusetts: - Brigham and Women's Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Academic/Other
To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT06412198
Sites in Massachusetts: - Massachusetts General Hospital Cancer Center — Boston, Massachusetts